Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) may be associated with chronic cough, as published in JAMA Otolaryngology–Head & Neck Surgery. A large study of more than 2 million people with type 2 diabetes across 70 healthcare organizations suggests that adults prescribed a GLP-1RA had a 12% higher risk for developing a new cough persisting for more than 8 weeks, compared with people prescribed other medications, including dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) …
Read More